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Abstract: Inactivating mutations of matrix metalloproteinase 2 (MMP2) cause multicentric 
  osteolysis with nodulosis and arthritis, one of a group of inherited osteolytic and arthritic 
  disorders. We have previously shown that mice lacking Mmp2 share similar syndromic features 
with the human disorder, and at the cellular level, Mmp2-/- mouse osteoblasts and osteoclasts have 
reduced numbers and proliferation rates at critical developmental time points. While previously 
hypothesized, the effect of MMP2 loss on apoptosis has not been examined in this system. We 
therefore sought to clarify its role in mediating the developmental defects in Mmp2-/- mice using 
immunohistochemistry, immunoblot analysis, and quantitative reverse transcription polymerase 
chain reaction analysis. We also explored the effects of MMP2 inhibition in the osteogenic sar-
coma cell line SaOS2. Loss of MMP2 resulted in increased apoptosis and caspase activation both 
in vitro and in vivo. MMP2-deficient cells had increased Fas expression and reduced levels of the 
key survival signals p-FAK, p-ERK, cFLIP, and Bcl-2. Notably, and in marked contrast to their 
original characterization, there was a significant increase in the in utero demise of homozygous 
Mmp2-/- embryos. Specifically, litters from heterozygous crosses consistently yielded nearly 
85% fewer than expected homozygous Mmp2-/- pups. Taken together, our findings highlight a 
new role for MMP2 in preventing apoptosis during development and growth.
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Introduction
Multicentric osteolysis with nodulosis and arthritis (MONA, MIM #259600) is one of a 
group of inherited “vanishing bone” disorders characterized by destruction of affected 
bones and joints that results from inactivating mutations in the matrix metalloproteinase 
2 (MMP2) gene.1 Mmp2-/- mice provide a unique model for study of the human disease, 
in that they share key clinically defining features of MONA, including progressive loss 
of bone mineral density, articular cartilage destruction, and abnormal long bone and 
craniofacial   development.2 These phenotypic changes are associated with marked and 
developmentally restricted in vivo decreases in osteoblast and osteoclast numbers.2 In 
part, decreased cell number in MMP2-deficient mice has been determined to be associ-
ated with decreased cellular proliferation rates.2 To further our understanding of how 
MMP2 loss results in this cellular phenotype and to return to a question we originally 
proposed, given the diverse role of MMP(s), we investigated whether there might also be Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
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a molecular mechanism by which MMP2-deficient osteoblasts 
undergo increased rates of apoptosis in addition to decreased 
rates of proliferation. Our studies demonstrate that through 
alteration of Fas and adhesion signaling cascades, MMP2-
deficient osteoblastic cell lines underexpress antiapoptotic 
factors, resulting in increased apoptosis. These findings add 
to the understanding of the importance of MMP2 in cellular 
and organismal biology.
Materials and methods
saOs2 cell culture and small  
interfering ribonucleic acid silencing
siMMP2 oligonucleotide (oligo) pools targeting human 
MMP2 were purchased from Dharmacon, Inc. Transfections 
were performed in serum-free media using Lipofectamine 
2000 (Invitrogen) and 100 pmol of oligo per well of a 12-well 
plate as previously described.3 Stable siMMP2 clones were 
generated as previously described.4
Quantitative reverse transcription 
polymerase chain reaction
Ribonucleic acid (RNA) was collected (Qiagen RNeasy Mini 
Kit) and treated with DNase (Qiagen). A total of 0.5 µg of 
RNA was reverse transcribed per reaction using first-strand 
complementary deoxyribonucleic acid (DNA) synthesis with 
random primers (Iscript, Bio-Rad Laboratories).
Quantitative reverse transcription polymerase chain reaction 
(RT-PCR) was performed on an ABI PRISM 7900HT sequence 
detection system (Applied Biosystems) using the primers 
listed in Table 1. Cycle number values were normalized with 
both glyceraldehyde 3-phosphate dehydrogenase and β-actin 
values. Values were analyzed as fold change compared with 
siLuciferase (non-targeting control oligonucleotide [siLuc]) 
or empty vector control values. Data shown are the average of 
three separate experiments, each done in triplicate. Statistical 
significance was determined by comparing fold change using the 
unpaired, two-tailed Student’s t-test assuming equal variances.
Adhesion assays
SaOS2 cells stably expressing siMMP2 oligos (siMMP2) or 
siLuc were plated at 150,000 cells per six-well matrix-coated 
plate in duplicate. All tissue culture plates and supplies were 
from BD Biosciences. Cells were photographed under a light 
microscope after 48 hours. Ten to 15 fields were photographed 
per well. Two independent experiments were performed to 
replicate results.
Fluoresence-activated cell sorting analysis
Cells were harvested from 12-well dishes and fixed in absolute 
ethanol (Sigma) for 24 hours. On the day of analysis, cells 
were pelleted and the absolute ethanol was removed. Cells 
were then stained with a 1 mL solution containing propidium 
iodide, RNase A, and phosphate-buffered saline (PBS). 
  Fluoresence-activated cell sorting (FACS) analysis was per-
formed on the FACSCalibur instrument (BD Biosciences).
immunoblot analysis
SaOS2 cell extracts were harvested in radioimmunopre-
cipitation assay buffer (Santa Cruz Biotechnology; standard 
protocol). Equal amounts of protein (50 µg; determined by 
the Bio-Rad DC protein quantification assay) were loaded 
and separated by PAGE and transferred to nitrocellulose 
membranes and probed with the specific antibodies listed in 
Table 2. Enhanced chemiluminescent immunoblot images 
were analyzed by scanning densitometry and quantified with 
Image J.5 Values were expressed as fold change relative to 
siLuc control.
caspase-9 activity assay
Caspase-9 activation state was assayed using the ApoTarget 
Caspase-9 Colorimetric Protease Assay (Biosource Interna-
tional, Invitrogen #KHZ0101) according to the   manufacturer’s 
protocol. Briefly, cells were harvested and lysed in the 
Table  1  Primers  used  for  quantitative  reverse  transcription 
polymerase chain reaction
Gene Forward Reverse
hMMP1 5′-cTGATGGcAcccA 
TTTAcAccT-3′
5′-GATcTGAGcGATGc 
cATcAAA-3′
hFas 5′-cATGcAGAAAGcA 
cAGAAAGG-3′
5′-GAcTTAGTGTcATG 
AcTccAGcA-3′
hcFLIP 5′-GAcTTGGcTGAAc 
TGcTcTAcAAGG-3′
5′-cTTATcTTGccTcG 
Gccc-3′
hBcl2 5′-AGGAAGTGAAcA 
TTcGGTGAc-3′
5′-GcTTcAGTTccAGG 
AccAGGc-3′
Table 2 Antibodies used for immunoblots and immunohisto-
chemical analysis
Antibody Manufacturer catalog number
cFliP cell signaling Technology 3210
cleaved caspase-3 cell signaling Technology 9661
cleaved caspase-8 calbiochem AM46
erK1/2, phosphorylated cell signaling Technology 9101
erK, total chemicon/Millipore MAB3054
FAK, phosphorylated chemicon/Millipore MAB1144
FAK, total Millipore/Upstate 06-543
Fas, ch11 Millipore/Upstate 05201
Glyceraldehyde 3-phosphate  
dehydrogenase
santa cruz Biotechnology  
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  supplied lysis buffer and quantified for protein concentration. 
Samples were then diluted to 1 µg/µL. Reaction mixture 
and LEHD-pNA-modified substrate were incubated at 37°C 
for 2 hours protected from light. Results were read using a 
microplate reader at 400 nm. Background absorbance was 
subtracted and fold change over siLuc caspase-9 levels 
determined. Levels were assayed in triplicate in two separate 
experiments.
Animals
Generation of the original founder Mmp2-/- mice used in these 
studies was described by Itoh et al6 and was done by targeted 
deletion of the promoter, 5′UTR, and exon 1 of the Mmp2 gene. 
Genotyping was done by PCR of genomic DNA extracted from 
tail snips or yolk sacs as described previously.4
All procedures were performed in accordance with an 
institutionally approved protocol for the use of animals in 
research.
histology and immunohistochemistry
Bones were isolated from age-matched Mmp2-/- and Mmp2+/+ 
mice and fixed in 10% phosphate-buffered formalin overnight 
and decalcified in cold ethylenediaminetetraacetic acid. Four 
micrometer-thick sagittal sections were stained with hematoxy-
lin and eosin. Sections were stained with antibodies to cleaved 
caspase-3 (asp 175) and counterstained with hematoxylin. Two 
methods of negative controls were used. The first substituted 
PBS alone for primary antibody, and the second used a con-
trol rabbit serum in place of primary antibody. Positive cells 
were counted using Bioquant TCW software (Nashville, TN, 
USA) and normalized to the trabecular bone surface area. 
Forty tibia and 40 femur areas (measuring 700×550 µm each) 
were counted from 12 sections (six Mmp2-/- and six Mmp2+/+) 
(see Table 2 for antibodies used and manufacturers).
embryo harvest
Pregnant females were sacrificed by cervical dislocation 7 or 
9 days postcoitus. Embryos were isolated and photographed 
using a dissecting microscope under 4× objective. Yolk sacs 
were washed in sterile PBS and DNA isolated for genotyp-
ing analysis.
Results
Targeted small interfering ribonucleic 
acid-mediated MMP2 knockdown induces 
apoptosis in cultured cell lines
Our initial hypothesis that increased rates of cellular apop-
tosis may be a consequence of loss of MMP2 expression 
was drawn from the altered cell morphology we detected in 
SaOS2 osteoblast cells treated with small interfering RNA 
to MMP2. In adhesion assays of these siMMP2 osteoblasts, 
we observed an increased number of cells displaying a 
characteristic fragmentation and “blebbing” of the plasma 
membrane suggestive of apoptosis (Figure 1A). To directly 
test this hypothesis, we generated two stable cell lines, 
siMMP2-A and siMMP2-B. Both demonstrated .60% 
knockdown of the MMP2 messenger RNA (mRNA) tran-
script and MMP2 activity (Figure 1F). Interestingly, we did 
not identify clones with a greater degree of knockdown. In 
hindsight, the inability to generate cells with a greater degree 
of knockdown may be a consequence of the resultant cel-
lular phenotype described herein. We assessed the amount 
of cell death in siMMP2 and control cells using propidium 
iodide staining for DNA content followed by FACS analysis 
to quantify cells in a subdiploid fragmented state (sub-G1). 
Remarkably, knockdown of MMP2 expression, even to 
these levels, resulted in three- to five-fold increased cell 
death compared with control cells (P,0.05, Figure 1B). 
We confirmed that increased cell death was induced through 
increased apoptosis, as opposed to necrosis or autophagy, 
by demonstrating a marked increase in caspase activation. 
Western blot analysis of cell lysates revealed over 30-fold 
increased levels of cleaved caspase-8 (p18) and caspase-3 
(p17/19) in siMMP2 clones compared with siLuc control 
clones (Figure 1C and D, respectively). Caspase-9 activity 
was also markedly increased in both clones compared with 
controls (P,0.05, Figure 1E).
rates of cellular apoptosis are  
increased in perinatal Mmp2-/- mice
The marked degree of apoptosis induced in this ex vivo iso-
lated cell culture system suggested a cell autonomous defect 
in the cells, possibly related to the cell autonomous defects 
we had previously identified in osteoblast differentiation and 
proliferation.2 This led us to investigate the in vivo level of 
apoptosis using Mmp2-/- mice. We had previously identified a 
reduced number of osteoblasts, osteoclasts, and proliferating 
cells in the bone marrow cavity of MMP2-deficient mice.2 
This finding suggested a defect in proliferation (which we 
had previously demonstrated2), an increase in apoptosis, or 
a combination of both. To test the possibility that apoptosis 
was also affecting cell numbers, we examined the tibias and 
femurs of 4-day-old Mmp2-/- mice for cleaved caspase-3, 
a marker of active apoptosis.
There was an increase in cells positive for cleaved 
caspase-3 in the marrow cavities of the Mmp2-/- mice Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
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Figure 1 MMP2-deficient SaOS2 clones demonstrate altered morphology, apoptosis, and caspase activation. 
Notes: (A) clones siMMP2-A and siMMP2-B have characteristic blebbing of cell membrane compared with siluc control cell line (arrowheads). (B) Quantification of fold 
change increase of sub-G1 fraction in siMMP2 clones. (C) increased caspase-8 cleavage (p18) in siMMP2 clones. (D) increased caspase-3 cleavage (p17/19) in siMMP2 clones. 
(E) increased caspase-9 activation in siMMP2 clones. (F) level of MMP2 mrnA expression (top graph) and MMP2 activity (bottom panel) in siMMP2 clones A and B compared 
with siluc control cells. *P,0.05 vs siluc control.
Abbreviations: MMP2, matrix metalloproteinase 2; mrnA, messenger ribonucleic acid; GADPh, glyceraldehyde 3-phosphate dehydrogenase.
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Figure 2 increased cleaved caspase-3 staining in matrix metalloproteinase 2 (Mmp2)-/- tibias. 
Notes: (A) Mmp2+/+ mice demonstrate cleaved caspase-3-positive cells in the hypertrophic chondrocytes (arrows) and occasionally on the bone surface (arrowhead). (B) 
Mmp2-/- mice reveal cleaved caspase-3-positive cells in the hypertrophic chondrocytes (arrows) and more frequently on the bone surface (arrowhead) compared with 
Mmp2+/+ sections. (C) number of cleaved caspase-3-positive bone lining cells (lc) is higher in Mmp2-/- mice compared with Mmp2+/+ mice. (D) number of cleaved caspase-3-
positive osteocytes (ocyt) is higher in Mmp2-/- mouse sections compared with Mmp2+/+. **P,0.005; *P,0.05 vs Mmp2+/+ sections.
  compared with those of control mice. Caspase-3-positive 
cells were mostly limited to the hypertrophic chondrocytes 
of the growth plate (arrows, Figure 2A and B). Microscopic 
examination revealed a greater than two-fold increase in 
the number of apoptotic lining cells along the endosteal 
and trabecular bone surface in the tibia, suggestive of an 
increased number of apoptotic osteoblasts (P,0.005, arrow-
heads, Figure 2A–C). By examining the number of positive 
staining osteocytes per bone area, a statistically significant 
upregulation of osteocyte apoptosis in both bones was dem-
onstrated (Figure 2D, **P,0.005, *P,0.05, respectively). 
These findings of increased in vivo apoptosis suggested that 
the reduced number of osteoblasts 4 days after birth could 
be due to increased cell death.
MMP2 inactivation alters activation  
of apoptotic and survival pathways
Having now identified increased levels of apoptosis both 
in vivo and in vitro in MMP2-deficient cells, we sought 
to investigate the potential mechanisms involved in the 
induction of apoptosis. We hypothesized that MMP2 could 
modulate death receptor pathway activation via cleavage of 
death receptors or their ligands. The Fas–FasL pathway was 
the primary candidate pathway because of its known strong 
effects on osteoblasts7 and because it has been shown to be 
affected by MMP2 loss in a number of other cell types.8–11 
Furthermore, activation of both caspase-8 and caspase-9 in 
our siMMP2 SaOS2 clones demonstrated involvement of 
both the extrinsic and intrinsic apoptotic pathways, a hallmark 
of Fas-mediated apoptosis.11
We therefore examined the levels of Fas expressed by 
MMP2-deficient osteoblasts. Fas protein levels were found 
to be increased between two- and six-fold in siMMP2A and 
siMMP2B, respectively (Figure 3). Of particular interest, 
and in marked contrast to protein levels, Fas mRNA levels 
were not increased (Figure 3). This disjunction between 
RNA and protein levels suggested that the increased pro-
tein levels could be the result of posttranscriptional and/or 
posttranslational regulation. Moreover, Fas mRNA levels 
were decreased ∼20% in the siMMP2-A clone compared 
with control (Figure 3, P,0.05). This suggested a selection 
for cells that have lower levels of Fas mRNA expression, 
as this would confer a survival advantage when there is 
altered Fas processing due to MMP2 loss. Fas generated in 
a bacterial cell expression system is sensitive to cleavage 
by MMP-7 but not MMP2.12 However, presentation of Fas 
on the cell surface, as well as variable levels of MMP-7 
(barely detectable at the mRNA level in our control or Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
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Figure 3 Increased levels of Fas in MMP2-deficient cells. 
Notes: MMP2-deficient clones display greater levels of Fas protein (A) but not 
increased levels of Fas mrnA (B). *P,0.05 vs siluc control.
Abbreviations: MMP2, matrix metalloproteinase 2; mrnA, messenger ribonucleic 
acid; GADPh, glyceraldehyde 3-phosphate dehydrogenase.
siMMP2 SaOS2 cells) and MMP2, could affect Fas cleav-
age in osteoblastic cells.
Activated caspase-3 is responsible for cleaving a large 
number of substrates, resulting in apoptotic propagation. Intrigu-
ingly, we had observed a decrease in cell adhesion in siMMP2 
clones (data not shown). One particularly relevant candidate 
substrate potentially responsible for mediating this decreased 
adhesion phenotype is FAK. FAK is an important member of 
focal adhesions that form at attachment points between cells 
and the matrix.13 Following the induction of apoptosis, FAK 
is cleaved from its full-length 120 kDa active form to inactive 
85 kDa and 77 kDa fragments.13 In siMMP2 clones, there are 
increased levels of these two cleavage products; the p85 fragment 
is increased ∼10%–20% (Figure 4B), while the later degradation 
product, p77, is increased six- to eight-fold (Figure 4C).
Phosphorylation of FAK takes place as part of the for-
mation of focal adhesions as cells become attached to their 
matrix. We found that the phosphorylation status of FAK in 
siMMP2 clones is decreased by 70%–90% compared with 
the control cells (Figure 4A). Since ERK phosphorylation 
and activation are important for osteoblast survival and 
proliferation, we postulated that p-ERK would be affected 
in MMP2-deficient systems with aberrant FAK signaling, 
survival, and proliferation. In accord with these, ERK phos-
phorylation was reduced to almost nondetectable levels in 
siMMP2 clones (Figure 4D).
MMP2-deficient cells have decreased 
expression of the antiapoptotic proteins 
cFliP and Bcl-2
Alterations in FAK and ERK signaling pathways may result in 
MMP2-deficient cells being more susceptible to Fas-mediated 
cell death via transcriptional changes. Transcription of the 
antiapoptotic caspase-8 inhibitor cellular FLICE-like inhibi-
tory protein (cFLIP) is decreased by adhesion loss.14–16 cFLIP 
is an endogenous dominant negative inhibitor of caspase-8 
(also known as Fas-linked interleukin 1β converting enzyme 
[FLICE]), and the balance between levels of caspase-8 and 
cFLIP can determine cellular susceptibility to death domain-
mediated apoptosis.14 In siMMP2 SaOS2 clones, cFLIP levels 
were reduced at both the mRNA and protein levels (Figure 5). 
Specifically, levels of cFLIP transcript in siMMP2 clones 
were decreased approximately 50% (P,0.005, Figure 5A). 
The p48 isoform, cFLIP(S), which has the greatest inhibi-
tory activity against caspase-8,17 was reduced by .70% at 
the protein level (Figure 5B).
Bcl-2, which is responsible for inhibiting the depolariza-
tion of the mitochondrial membrane and cytochrome C release, 
can be upregulated in response to a number of differentiation 
and survival signals, particularly involving ERK activation.18 
In agreement with the decreased level of ERK phosphoryla-
tion in MMP2-deficient cells, Bcl-2 mRNA expression levels 
were reduced .60% (P,0.0005, Figure 5C). The sum of 
these alterations in apoptotic regulators implies an increased 
susceptibility to Fas-mediated apoptosis.
MMP2-deficient cells have increased levels of Fas pro-
tein, as well as loss of antiapoptotic signaling pathways and 
proteins that may normally suppress apoptosis induced by 
Fas. These findings could explain the increased apoptosis in 
MMP2-deficient SaOS2 cells after activation of the Fas path-
way, and in MMP2-deficient Jurkat cells (data not shown), 
which are known to be highly sensitive to Fas-mediated 
apoptosis.16,19
MMP2 deficiency results in reduced 
embryonic survival in mice
As we explored the mechanistic causes of increased apoptotic 
susceptibility, we began to synthesize a series of   observations 
from the clinical and basic science aspects of MMP2 
deficiency. First, our recent description of cardiac defects 
in multiple MONA families suggested that an extraskeletal 
phenotype may also be caused by MMP2 loss.20,21 In each of 
these families, a number of MMP2-deficient individuals were 
born with developmental heart defects, including septal and Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
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Figure 4 Loss of FAK phosphorylation, increased FAK degradation, and loss of ERK phosphorylation in matrix metalloproteinase 2 (MMP2)-deficient cells. 
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vessel defects. Second, the Fas, FAK, and ERK pathways and 
proteins affected by MMP2 loss are not specific to osteoblast 
function. They are key regulators of critical developmental 
pathways in multiple cell types and organ systems. Finally, 
and as fully detailed as follows, breeding of heterozygous 
mice results in fewer Mmp2-/- pups than expected. Taken 
together, these observations led us to reinvestigate the pos-
sibility of embryonic lethality in Mmp2-/- mice.
In our experiments, and in marked contrast to the original 
characterization of Mmp2-/- mice,6 litters from heterozygous 
crosses consistently yielded fewer than expected Mmp2-/- 
pups (Table 3). Based on expected numbers, there was an 
85% reduction in the number of knockout pups born from 
  heterozygote crosses. From 14 heterozygous crosses yielding a 
total of 104 live pups, only four Mmp2-/- pups were generated. 
This low number deviated markedly from the ∼20 expected 
(χ2=22.5, P,0.0001). A number (n=23) of pups were found 
partially cannibalized; unfortunately, these could not be 
genotyped and their genetic status is unknown, limiting our 
functional analysis.
To investigate the timing and plausible causes for this 
discrepancy, we examined the embryonic development of 
these mice. At both days E9.5 and E7.5, fewer knockout 
embryos were observed than expected. At E9.5, there was a 
40% reduction in the expected number of knockout embryos 
from Mmp2+/- × Mmp2-/- crosses. Instead of the expected 1:1 Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
214
Mosig et al
Table 3 reduced number of matrix metalloproteinase 2 (MMP2)-/- 
pups from MMP2+/- heterozygous crosses
Cross +/+ (exp) +/- -/-
+/- × +/- (14 litters;  
104 pups delivered)
34 (26) 43 (52) 4 (26)
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Figure 5 Reduced levels of cFLIP and Bcl2 in MMP2-deficient cells. 
Notes: siMMP2 clones A and B have significantly reduced levels of cFLIP at the mRNA (A) and protein (p58/48) levels (B) compared with siluc control. (C) siMMP2 clones 
A and B have significantly reduced levels of Bcl2 mRNA. **P,0.005; ***P,0.0005; ****P,0.00005.
Abbreviations: MMP2, matrix metalloproteinase 2; mrnA, messenger ribonucleic acid; GADPh, glyceraldehyde 3-phosphate dehydrogenase.
ratio, there were only seven Mmp-/- embryos identified in the 
total of 23 embryos (χ2=3.522, P=0.06). In addition, surviv-
ing E9.5 Mmp2-/- embryos were dwarfed compared with 
Mmp2+/- embryos (Figure 6). As shown in Figure 6D, in some 
instances, Mmp2-/- embryos were chaotically disorganized 
and appeared as cell masses with no clearly recognizable 
embryonic features.
At day E7.5, there was a 45% reduction in the expected 
number of Mmp2-/- embryos. Rather than the nine Mmp2-/- 
embryos expected from a total of 18 embryos, only five 
were Mmp2-/-(χ2=3.556, P=0.06). The surviving knock-
out embryos were shorter and had an average length of 
689 µm compared with 827 µm for heterozygote embryos 
(Figure 7). This size difference, while not achieving 
statistical significance, was suggestive of a trend toward 
a growth defect (P=0.06, Figure 7C) and was in accord 
with the growth differences seen at day E9.5. Aside from 
smaller size, the Mmp2-/- embryos appeared morphologi-
cally normal.
Discussion
These results demonstrating a novel role for MMP2 in 
regulating apoptotic and survival pathways expand upon 
the current known function of MMP2 in modulating cell 
behavior. We have shown that loss of MMP2, both in vivo 
and ex vivo, induces cellular apoptosis. In vivo, the increased 
levels of apoptosis may contribute to the reduced viability 
of Mmp2-/- mouse embryos and pups as well as the skeletal 
features that define the surviving Mmp2-/- mice. We identi-
fied an increased level of Fas expression in siMMP2 clones. Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
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Our studies of MMP2 deficiency and the Mmp2-/- mouse 
identify a novel role for MMP2 as an antiapoptosis molecule 
and provide the mechanistic link and rationale for future 
studies. As our studies demonstrate, there is an increased 
number of apoptotic osteoblasts in the marrow cavity and 
bone of 4-day-old Mmp2-/- mice. Based on our molecular 
studies thus far, it appears this is the sum of removal of 
survival factors/signals (proper adhesion, FAK and ERK 
signaling, cFLIP and Bcl-2 expression) and inappropri-
ate activation of apoptotic factors/signals (Fas signaling, 
caspase activation). It is difficult to isolate any one of 
these defects as being the most important or physiologi-
cally present in vivo. Of note, individual overexpression or 
knockout of a number of these factors results in abnormal 
skeletal phenotypes. Loss of integrin-1 disrupts cell adhe-
sion and results in premature osteoarthritis.22 Caspase-3 
deficiency, surprisingly, causes decreased bone formation 
and osteoblastogenesis.23 FasL-deficient mice that lack Fas 
signaling have increased bone mass and increased osteoblast 
colony formation, which represents the opposite pheno-
type to the Mmp2-/- mouse.24,25 Either Bcl-2 deficiency or 
overexpression affects osteoblast adhesion, differentiation, 
and apoptosis.26,27 Mice deficient in FAK, caspase-8, and 
cFLIP are all embryonic lethal. Therefore, their specific 
roles in skeletal development have not been studied.28–32 
Future studies of Mmp2-/- mice should allow dissection of 
these changes and a greater understanding of their role in 
human disease and normal physiology.
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Figure 6 representative images of matrix metalloproteinase 2 (Mmp2)+/- (A, B) and Mmp2-/- (C, D) embryos at e9.5.
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Figure 7 representative matrix metalloproteinase 2 (Mmp2)+/- (A) and Mmp2-/- 
(B) embryos at e7.5. (C) lengthwise measurements of Mmp2-/- embryos revealed 
they were marginally shorter than Mmp2+/- embryos.
Note: *P=0.06.
Furthermore, we demonstrated that loss of MMP2 causes 
decreased FAK and ERK phosphorylation and increased 
FAK degradation. These signaling aberrations could induce 
the decreased levels of two apoptosis inhibitors, cFLIP and 
Bcl-2, which we also identified in siMMP2 clones.Advances in Genomics and Genetics 2014:4 submit your manuscript | www.dovepress.com
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Taken together, our data suggest a dual role for MMP2 
in osteoblast biology. MMP2 facilitates adhesion as well as 
the removal of a “death” signal. Both of these actions could 
take place at the cell membrane. MMP2 activity could be 
targeted and concentrated pericellularly via the formation of 
complexes containing MMP2 and transmembrane proteins 
such as integrins or MT1-MMP.33–35 These interactions 
may originate intracellularly along the secretory pathway,36 
which could explain why addition of exogenous MMP2 does 
not rescue the MMP2-deficient phenotype.2,4 Secondly, as 
MMP2 is released from the membrane into serum or con-
ditioned media, it may remain in complex with TIMPs to 
prevent unregulated cleavage of matrix or serum proteins. 
This would further obstruct MMP2’s access and activity at 
the cell membrane upon addition to MMP2-deficient cells.
As cells adhere to a surface, MMP2, localized to the 
cell surface, may be responsible for cleavage, activation, 
or organization of either cell adhesion molecules or the 
matrix itself. In MMP2-deficient systems, these substrates 
go unprocessed, resulting in altered cell shape and adhesion. 
Within the cell, this may contribute to the reduced levels of 
phosphorylated FAK and ERK, which, in turn, could result 
in decreased levels of Bcl-2 and cFLIP. At the same time, 
MMP2 loss causes increased levels of Fas, resulting in 
increased Fas signaling.
Increased Fas activation is a primary candidate to explain 
the increased apoptosis in MMP2-deficient osteoblasts. Stud-
ies have shown that Fas activation in osteoblasts represses 
differentiation but does not induce apoptosis.7 However, this 
study was done in an MMP2-sufficient system. In MMP2-
deficient cells, which are characterized by their reduced 
adhesion, reduced FAK and ERK activation, and reduced 
expression of Bcl-2 and cFLIP, the threshold for Fas-medi-
ated apoptosis may be lower. Therefore, increased levels of 
Fas without these prosurvival signals would result in not just 
reduced differentiation but also increased apoptosis.
The role of MMP2 in cardiac development based on the 
finding of occasional cardiac defects in MONA patients20,21,37 
and the known expression and role of MMP2 in rat and 
chicken cardiogenesis38,39 is, unfortunately, incomplete. 
Nonetheless, in these studies, it was noted that at the 
embryonic time points directly before and after looping of 
the embryonic heart tube to begin chambered heart develop-
ment and septation there was a nearly equal reduction in the 
number of Mmp2-/- mice. It therefore appears that twisting 
of the heart tube is not directly affecting embryonic survival; 
rather, there is a more widespread disruption causing death 
prior to this point. This could be due to defects in implantation 
or other early stages, although we have not yet investigated 
this. Subsequent to cardiac looping, there is further loss of 
embryos, resulting in the highly significant loss of Mmp2-/- 
pups at birth. Therefore, it is possible that subsequent stages 
of cardiac development are affected by MMP2 loss. Studies 
to understand the causes of embryonic lethality, as well as 
the survival, of Mmp2-/- mice are ongoing.
The increased osteoblast cell death found in Mmp2-/- 
bones results in improper and incomplete bone modeling 
and remodeling early in life. Concomitantly, there is also 
decreased proliferation and adhesion of MMP2-deficient 
osteoblasts that may further disable matrix secretion and 
bone formation. The knowledge gained from these studies 
of MMP2 biology may contribute to a greater understanding 
of bone modeling and remodeling, osteoblast differentiation, 
and apoptosis in general.
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